<DOC>
	<DOCNO>NCT02390375</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety DW0929 patient primary hypercholesterolemia</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety DW0929 Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Adult 19years Patients primary hypercholesterolemia whose LDLC level 250mg/dL TG level 350mg/dL Patients whose LDLC level 'Anti dyslipidemia drug administration consider standard ' NCEP ATP III ( 2004 ) Those voluntarily write consent participate clinical trial Uncontrolled hypertension Severe renal impairment ( CrCl &lt; 30mL/min ) Those active liver disease whose ALT , AST level great twice upper limit normal Serum creatinine &gt; 2.0mg/dL Those geunyukbyeong rhabdomyolysis cause use statin hypersensitivity ezetimibe Combined cyclosporine treat patient HbA1c ≥ 9 % TSH ≥ 1.5 X ULN HIVpositive person Congestive heart failure patient classify NYHA Class III IV Patients uncontrolled arrhythmia Patients malignant tumor need chemotherapy , radiation therapy , etc . Blood clot disorder Patients myocardial infarction within 6 month cardiovascular bypass surgery , patient underwent angioplasty Patients history anxiety severe typical peripheral arterial disease within three month Women childbearing age n't agree contraception clinical trial Pregnant woman nurse mother Those take drug combination taboo Who treat another investigational drug within 30 day Unsuitable character clinical trial test self determination</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>